However, these boundaries can be plastic, and studies in pre-clinical and clinical contexts have identified CD4+ T cells that not only express key molecules associated with cytolytic granules such as granzymes (GZM) and perforin (PRF1), but also possess direct cytotoxicity that underlies both pathogenic and protective immunity, including in cancer. The gene discussed is CD4; the disease is cancer.